Agenda

VIRTUAL ONLY!

 

Thursday, Sep 15 Friday, Sep 16

Thursday, September 15, 2022

08:15 am - 08:20 am EST
Welcome and Introduction

Tom Misteli, Ph.D.
Director
Center for Cancer Research, NCI

08:20 am - 08:30 am EST
Tribute to Dr. Tom Waldman

Chair: Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI

SESSION I: CAR T-Cell Based Immunotherapies

Chair: Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI

08:30 am - 09:00 am EST
Building on CD19 CAR Therapy to Tackle Solid Tumors

Michel Sadelain, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

09:00 am - 09:30 am EST
Chimeric Antigen Receptor T-Cell Therapy for Lymphoma and Multiple Myeloma

James Kochenderfer, M.D., Center for Cancer Research, NCI

09:30 am - 10:00 am EST
NK Cells: Next Generation Cell Therapies for Cancer

Katy Rezvani, Ph.D., MD Anderson Cancer Center

10:00 am - 10:30 am EST
Factors Affecting Outcomes of CD19 CAR-T Immunotherapy for B Cell Malignancies

Cameron Turtle, Ph.D., Fred Hutchinson Cancer Research Center

10:30 am - 10:50 am EST
BREAK
10:50 am - 11:20 am EST
CAR T-Cell Therapy in Pediatric Leukemia: Current Status and Future Directions

Nirali Shah, M.D., M.H.Sc., Center for Cancer Research, NCI

SESSION II: Cell Therapy for Solid Epithelial Cancers

Chair: Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI

11:20 am - 11:50 am EST
Lymphocytes as a “Living Drug” for the Immunotherapy of Cancer

Steven Rosenberg, M.D., Ph.D., Center for Cancer Research, NCI

11:50 am - 12:20 pm EST
Updates with CAR T Cells

Carl June, M.D., Perelman School of Medicine, University of Pennsylvania

12:20 pm - 01:30 pm EST
LUNCH & VIRTUAL POSTER VIEWING
01:30 pm - 02:00 pm EST
T-Cell Therapy for Viral and Non-Viral Epithelial Cancers

Christian Hinrichs, M.D., Rutgers Cancer Institute of New Jersey

02:00 pm - 02:30 pm EST
Non-viral Precision T Cell Receptor Replacement for Personalized Adoptive Cell Therapy in Patients with Refractory Solid Cancers

Stefanie Mandl, Ph.D., PACT Pharma

02:30 pm - 03:00 pm EST
Engineering and/or Modulating T Cells to be Effective in Hostile Tumor Microenvironments

Philip Greenberg, M.D., Fred Hutchinson Cancer Research Center

03:00 pm - 03:30 pm EST
CAR T cells for Solid Tumors:  Charting a Path Forward

Crystal Mackall, M.D., Stanford University

03:30 pm - 03:50 pm EST
BREAK
SESSION III: Principles of Checkpoint Modulators

Chair: James Gulley, M.D., Ph.D., Center for Cancer Research, NCI

03:50 pm - 04:20 pm EST
Immune Checkpoint Blockade in Cancer Therapy: Historical Perspective, New Opportunities, and Prospects for Cures

James Allison, Ph.D., The University of Texas 

04:20 pm - 04:50 pm EST
Discovery of New IO Targets and Mechanisms Leveraging CRISPR

Arlene Sharpe, M.D., Ph.D., Harvard University

04:50 pm - 05:20 pm EST
From the Clinic to the Lab: Evaluating Mechanisms of Response and Resistance to Immune Checkpoint Therapy. 

Padmanee Sharma, M.D., Ph.D., The University of Texas

05:20 pm EST
ADJOURN

Friday, September 16, 2022

SESSION IV: Clinical Applications of Checkpoint Modulators

Chair: James Gulley, M.D., Ph.D., Center for Cancer Research, NCI

08:30 am - 09:00 am EST
Neoadjuvant Checkpoint Blockade for Cancer Therapy

Suzanne Topalian, M.D., Johns Hopkins University

09:00 am - 09:30 am EST
Immunotherapy for Melanoma: Interventions for Checkpoint Blockade Resistance

Jedd Wolchok, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

09:30 am - 10:00 am EST
Novel Immunotherapy Approaches for HPV Associated Cancers

James Gulley, M.D., Ph.D., Center for Cancer Research, NCI

SESSION V: Microbiomes and Immunotherapy

Chair: James Gulley, M.D., Ph.D., Center for Cancer Research, NCI

10:00 am - 10:30 am EST
Tumor and Host Factors Regulating Anti-Tumor Immunity and Immunotherapy Efficacy

Thomas Gajewski, M.D., Ph.D., University of Chicago

10:30 am - 10:50 am EST
BREAK
10:50 am - 11:20 am EST
Targeting the Gut and Tumor Microbiome in Cancer

Jennifer Wargo, M.D., The University of Texas

11:20 am - 11:50 am EST
Integrating the Microbiota in Our Understanding of Cancer Immunosurveillance

Laurence Zitvogel, M.D., Gustave Roussy Cancer Center

11:50 am - 12:50 pm EST
LUNCH & VIRTUAL POSTER VIEWING
SESSION VI: Factors Influencing the Success of Immunotherapy

Chair: Claudia Palena, Ph.D., Center for Cancer Research, NCI

12:50 pm - 01:20 pm EST
Predicting Outcome and Inferring Mechanisms of Tumor Immunity from Human Samples

Nir Hacohen, Ph.D., Massachusetts General Hospital 

01:20 pm - 01:50 pm EST
Response and Resistance to PD-1 Blockade Therapy

Antoni Ribas, M.D., Ph.D., University of California, Los Angeles

01:50 pm - 02:20 pm EST
Tumor Plasticity, Extracellular Matrix, and Resistance to Immunotherapy

Claudia Palena, Ph.D., Center for Cancer Research, NCI

SESSION VII: Innovative Approaches to Immunotherapy

Chair:  Claudia Palena, Ph.D., Center for Cancer Research, NCI

02:20 pm - 02:50 pm EST
Immuno-oncology Beyond Checkpoint Inhibition and T Cell Transfer

Sofia Gameiro, Ph.D., Center for Cancer Research, NCI

02:50 pm - 03:20 pm EST
Modulating the Metastatic Microenvironment for Therapeutic Gain

Rosandra Kaplan, M.D., Center for Cancer Research, NCI

03:20 pm - 03:50 pm EST
BREAK
03:50 pm - 04:20 pm EST
Concerted Antibody Drug and Target Discovery in Hematologic Malignancies

Christoph Rader, Ph.D., Scripps Research

04:20 pm - 04:50 pm EST
Altering Host Immunity with Targeted Photoimmunotherapy

Peter Choyke, M.D., F.A.C.R., Center for Cancer Research, NCI

04:50 pm EST
ADJOURN